Dr. Emmett Cunningham and Scott Requadt Promoted From Principals
CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., Jan. 5 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture capital firm, announced today the promotions of Emmett Cunningham, M.D., Ph.D., M.P.H., to Partner and Scott Requadt, J.D., M.B.A., to Transactional Partner, effective Jan. 1, 2009.
Dr. Cunningham joined Clarus in 2006 and represents the firm as a Director on the Board of SARcode and as a Board Observer at FerroKin, Pearl, Taligen and Zogenix. He is also a member of the Scientific Advisory Boards of ESBATech and CoMentis. Dr. Cunningham joined Clarus from Eyetech Pharmaceuticals, where he was Senior Vice President of Medical Strategy and helped build and lead the development and commercialization of Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, where he was responsible for the clinical development of early-phase CNS compounds and the in-licensing of early- and late-stage therapeutic candidates in ophthalmology.
In addition to his extensive clinical, scientific and operating experience in the pharmaceutical, biotech and medtech industries, Dr. Cunningham is an internationally recognized specialist in eye diseases with more than 200 publications. In addition to his investing responsibilities at Clarus, he is an Adjunct Clinical Professor of Ophthalmology at
"Emmett has demonstrated a superior understanding of a wide
|SOURCE Clarus Ventures, LLC|
Copyright©2009 PR Newswire.
All rights reserved